Challenge: hepatitis C transmission among persons who inject drugs.




Globally, about 50 per cent of persons who inject drugs have been infected with hepatitis C virus (HCV). Prevention requires access to harm-reduction services, i.e., sterile needles, opioid substitution therapy and testing and treatment for hepatitis C. Yet only a few countries (e.g., Australia, Canada) provide adequate harm-reduction services, underscoring the need for greater investment and political will to protect populations most vulnerable to hepatitis C.


Comments

Popular posts from this blog

Let’s Break It Down.

Global Webinar to mark the World Hepatitis Day 2025.

World Hepatitis Day 2025 Launch Event.